Lorcaserin HCl Data to be Presented a...
Home  »  Community News  »  Lorcaserin HCl Data ...
Lorcaserin HCl Data to be Presented at American Diabetes Association’s 75th Scientific Sessions
Pharma News, Upcoming Events & Interviews
, , , , ,

Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) announced today that the following poster regarding lorcaserin HCl will be presented at American Diabetes Association’s 75th Scientific Sessions taking place June 5-9, 2015, in Boston, Massachusetts:

Impact of Sulfonylurea Use on Weight Loss Achieved with Lorcaserin
Poster Number: 299-LB

This post-hoc analysis evaluated the impact of sulfonylurea use on weight loss and glycemic parameters achieved with lorcaserin in patients with type 2 diabetes mellitus over 52 weeks.

About BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management

Lorcaserin is marketed in the United States under the brand name BELVIQ. BELVIQ is a serotonin 2C receptor agonist approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m2 or greater (obese), or BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes the risk of heart problems or stroke, or death due to heart problems or stroke. BELVIQ is also approved for weight management in South Korea.

For more information about BELVIQ, click here for the full Product Information or visitwww.BELVIQ.com.

Leave a reply

You must be logged in to post a comment.